Lilly is trying to tackle a fundamental issue with the GLP-1 medicines that have transformed obesity treatment. Patients are losing a lot of weight but have little interest in taking injections for ...

Eli Lilly and Company today announced detailed results from two late-phase trials showing that people with obesity maintained their weight loss long term with either Foundayo or lower-dose Zepbound ...

Eli Lilly said on Tuesday that patients in ​a late-stage trial who had been taking an injectable GLP-1 medication for over a ...

In recent years, weight-loss drugs have become a common addition to diet and exercise routines. The rise of GLP-1 medications ...

GoodRx reports that Foundayo, a new oral weight-loss pill, is FDA-approved for obesity treatment, offering an alternative to ...

GLP-1 shots and pills both help regulate appetite and blood sugar. Learn the differences in effectiveness, cost, and who ...

We reviewed popular telehealth and pharmacy options for finding Zepbound online. Here are the top providers for safe access and ongoing support.

Eli Lilly and Company today announced an additional $4.5 billion investment across two of its three Lebanon sites?bringing the company's total Indiana capital expansion commitments since 2020 to more ...

Until recently, the most effective new obesity medications, including semaglutide (Wegovy) and tirzepatide (Zepbound), were ...

Wegovy (semaglutide) and Zepbound (tirzepatide) are commonly prescribed medications for weight management. Semaglutide, the first weekly injectable glucagon-like peptide-1 (GLP-1) receptor agonist, ...

A new University of Washington (UW) survey is raising new questions about drug use trends in the region, showing a sharp reported decline in injection drug use while fueling debate over how best to ...